AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12047207 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 36
Study 12047207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair sitting position
Number of subjects: 36
Study 12047207 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down tilt position
Number of subjects: 36
Study 9866379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass screening for prostatic cancer (submitted to screening 1 year ago)
Number of subjects: 186
Study 9866379 — intervention group
Group type: COMPARATOR
Intervention: No mass screening (not submitted for 3 years)
Number of subjects: 186
Study 8562236 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hypothermic cardioplegia
Number of subjects: 24
Study 8562236 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous normothermic blood cardioplegia
Number of subjects: 24
Study 2679829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound (OHC) treatment providing 1.6 g calcium, 0.74 g phosphorus, and 1.94 g noncollagen peptides per day
Number of subjects: 48
Study 2679829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 2679829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound (OHC) treatment
Number of subjects: 48
Study 2679829 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progesterone substitution in poor responders
Number of subjects: 48
Study 4157353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin for 10 days
Number of subjects: 128
Study 4157353 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin for 10 days
Number of subjects: 128
Study 4157353 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin (single injection)
Number of subjects: 128
Study 30605396 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy (HT)
Number of subjects: 11
Study 30605396 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral intervention (Control)
Number of subjects: 11
Study 28293099 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorimetric assessment of vaginal pH
Number of subjects: 1216
Study 28293099 — intervention group
Group type: COMPARATOR
Intervention: Nugent score > 7 (gold standard)
Number of subjects: 1216
Study 25944606 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of gestational sac volume in physiological pregnancies
Number of subjects: 413
Study 25944606 — intervention group
Group type: COMPARATOR
Intervention: Measurement of gestational sac volume in missed abortion
Number of subjects: 413
Study 25944606 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of gestational sac size and pregnancy development
Number of subjects: 413
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone single doses (200, 400, and 600 mg)
Number of subjects: 20
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone multiple doses (400 mg, 3 times daily)
Number of subjects: 20
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐carboxy‐pirfenidone (metabolite)
Number of subjects: 20
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of pirfenidone
Number of subjects: 20
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of unchanged pirfenidone
Number of subjects: 20
Study 23580109 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 20
Study 21317789 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMHaVi program (exercise and health education)
Number of subjects: 74
Study 21317789 — intervention group
Group type: COMPARATOR
Intervention: Normal care of a physician in pediatrics (control)
Number of subjects: 74
Study 19762765 — intervention group
Group type: COMPARATOR
Intervention: IVRA lidocaine plus IV saline (Group 1)
Number of subjects: 60
Study 19762765 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA lidocaine and paracetamol (300 mg) admixture plus IV saline (Group 2)
Number of subjects: 60
Study 19762765 — intervention group
Group type: COMPARATOR
Intervention: IVRA lidocaine plus IV paracetamol (300 mg) (Group 3)
Number of subjects: 60
Study 17823676 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite core with prefabricated posts
Number of subjects: 45
Study 17823676 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam core with prefabricated posts
Number of subjects: 45
Study 17823676 — intervention group
Group type: COMPARATOR
Intervention: Glass-ionomer core with custom post
Number of subjects: 45
Study 17823676 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite core with prefabricated posts
Number of subjects: 45
Study 15072715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg twice daily
Number of subjects: 32
Study 15072715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 125 mg twice daily
Number of subjects: 32
Study 15072715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14665887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol/l CAP diluted in glucidic solvent
Number of subjects: 39
Study 14665887 — intervention group
Group type: COMPARATOR
Intervention: 100 nMol/l RTX diluted in 10% ethanol
Number of subjects: 39
Study 11197264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine therapy (4 g daily for 18 months)
Number of subjects: 318
Study 11197264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 11197264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine therapy (in subgroup with isolated small bowel Crohn's disease)
Number of subjects: 318
Study 11197264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with isolated small bowel Crohn's disease)
Number of subjects: 318
Study 9250794 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (110 or 220 MBq of 111In‐pentetreotide)
Number of subjects: 35
Study 9250794 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy
Number of subjects: 35
Study 8048662 — intervention group
Group type: EXPERIMENTAL
Intervention: Venodilators (sustonit-mitte)
Number of subjects: 92
Study 8048662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed vasodilators and arteriolodilators (prazosin, cordafen)
Number of subjects: 92
Study 8048662 — intervention group
Group type: COMPARATOR
Intervention: Venodilators
Number of subjects: 92
Study 3469935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmenoxime plus amikacin
Number of subjects: 101
Study 3469935 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus amikacin
Number of subjects: 101
Study 28527646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control (4-6 mmol/l, IV insulin, n = 9)
Number of subjects: 18
Study 28527646 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (6-10 mmol/l, SC insulin, n = 9)
Number of subjects: 18
Study 26179771 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks
Number of subjects: 40
Study 26179771 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 40
Study 25364081 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP and telemedicine (n = 54)
Number of subjects: 107
Study 25364081 — intervention group
Group type: COMPARATOR
Intervention: Standard care CPAP (n = 53)
Number of subjects: 107
Study 25364081 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 107
Study 23936985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product-restricted diets (intervention group)
Number of subjects: 62
Study 23936985 — intervention group
Group type: COMPARATOR
Intervention: Liberal diets (control group)
Number of subjects: 62
Study 20945990 — intervention group
Group type: EXPERIMENTAL
Intervention: CinnoVex™
Number of subjects: 70
Study 20945990 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex®
Number of subjects: 70
Study 20945990 — intervention group
Group type: COMPARATOR
Intervention: Rebif®
Number of subjects: 70
Study 20945990 — intervention group
Group type: COMPARATOR
Intervention: Betaferon®
Number of subjects: 70
Study 20945990 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 19140845 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta (3000 IU)
Number of subjects: 112
Study 19140845 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta (6000 IU)
Number of subjects: 112
Study 19140845 — intervention group
Group type: COMPARATOR
Intervention: Control (2 or 3 times per week administration of epoetin-beta)
Number of subjects: 112
Study 16775089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell transplantation (BMT)
Number of subjects: 20
Study 16775089 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow supernatant (control)
Number of subjects: 20
Study 14687422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Tissue Doppler Imaging (TDI) of Arterial Wall Motion (AWM)
Number of subjects: 126
Study 10377609 — intervention group
Group type: EXPERIMENTAL
Intervention: blackcurrant/calcium concentrate
Number of subjects: 15
Study 10377609 — intervention group
Group type: EXPERIMENTAL
Intervention: blackcurrant/calcium drink
Number of subjects: 15
Study 10377609 — intervention group
Group type: EXPERIMENTAL
Intervention: apple & blackcurrant concentrate
Number of subjects: 15
Study 10377609 — intervention group
Group type: EXPERIMENTAL
Intervention: orange concentrate
Number of subjects: 15
Study 10377609 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 15
Study 8878339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment administered when well
Number of subjects: 12
Study 8878339 — intervention group
Group type: COMPARATOR
Intervention: No bright light treatment until first symptoms of depression
Number of subjects: 12
Study 1300312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg, two tablets a day for 90 days)
Number of subjects: 40
Study 1300312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6387952 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (chemonucleolysis)
Number of subjects: 0
Study 6387952 — intervention group
Group type: COMPARATOR
Intervention: Surgical management techniques
Number of subjects: 0
Study 6387952 — intervention group
Group type: COMPARATOR
Intervention: Conservative management techniques
Number of subjects: 0
Study 31722024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone hydrochloride 800 μg per 1 mL
Number of subjects: 197
Study 31722024 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone hydrochloride 800 μg per 1 mL
Number of subjects: 197
Study 31722024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 197
Study 31722024 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone
Number of subjects: 197
Study 28917592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal tDCS (n=16); anode-left-prefrontal/cathode-right-sensory
Number of subjects: 58
Study 28917592 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor tDCS (n=14); anode-motor/cathode-right prefrontal
Number of subjects: 58
Study 28917592 — intervention group
Group type: COMPARATOR
Intervention: Active-Control tDCS (n=15); anode-left-temporal-occipital junction/cathode-medial-anterior-premotor-area
Number of subjects: 58
Study 28917592 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=13); 0 mA-current stimulation
Number of subjects: 58
Study 26372368 — intervention group
Group type: COMPARATOR
Intervention: Gender dialogue groups in addition to group savings for child brides
Number of subjects: 682
Study 26372368 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention arm for nonchild brides
Number of subjects: 682
Study 22554394 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site education with an academic detailer
Number of subjects: 64
Study 22554394 — intervention group
Group type: COMPARATOR
Intervention: Quitline materials delivered by mail
Number of subjects: 64
Study 21926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 (IG1) - attended the program and received a take-home pack
Number of subjects: 60
Study 21926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (IG2) - received a take-home pack only
Number of subjects: 60
Study 21926651 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG) - received no intervention
Number of subjects: 60
Study 19461552 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (45-min treatment, sensory, biphasic square wave stimulation, 150-mus phase duration, 150 pps)
Number of subjects: 33
Study 19461552 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal knee joint cooling (20-min treatment with two 1.5-L ice bags)
Number of subjects: 33
Study 19461552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 17717439 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard burn care plus oxandrolone (0.1 mg/kg body weight q.12 hours p.o, n = 45)
Number of subjects: 235
Study 17717439 — intervention group
Group type: COMPARATOR
Intervention: Standard burn care (control, n = 190)
Number of subjects: 235
Study 15072733 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced use of cosmetics with special instructions on skin care
Number of subjects: 48
Study 11870016 — intervention group
Group type: EXPERIMENTAL
Intervention: E-EPA (ethyl ester of eicosapentaenoic acid)
Number of subjects: 20
Study 11870016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9670348 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 231
Study 9670348 — intervention group
Group type: COMPARATOR
Intervention: Weighted-Play-the-Winner (WPW) design
Number of subjects: 231
Study 9670348 — intervention group
Group type: COMPARATOR
Intervention: WPWI (Weighted-Play-the-Winner with inheritance)
Number of subjects: 231
Study 7827669 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 63
Study 7827669 — intervention group
Group type: COMPARATOR
Intervention: Nonasthmatic children (control group)
Number of subjects: 63
Study 2365876 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips TL12 fluorescent lamps (UVB/UVC ratio 8.7)
Number of subjects: 0
Study 2365876 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolff Helarium lamps (UVB/UVC ratio greater than 1300)
Number of subjects: 0
Study 742355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Melfalan (Group A)
Number of subjects: 79
Study 742355 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with adriamycin and Melfalan (Group B)
Number of subjects: 79
Study 742355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Melfalan (Group A) among premenopausal patients
Number of subjects: 79
Study 742355 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among premenopausal patients
Number of subjects: 79
Study 742355 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Melfalan (Group A) among postmenopausal patients
Number of subjects: 79
Study 742355 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with adriamycin and Melfalan (Group B) among postmenopausal patients
Number of subjects: 79
Study 6981171 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320 mg of TMP and 1,600 mg of SMZ daily for 14 days
Number of subjects: 60
Study 6981171 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 2 g daily for 14 days
Number of subjects: 60
Study 6981171 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 60
Study 29113530 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 30
Study 29113530 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 30
Study 27665852 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 81
Study 27665852 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 81
Study 24797396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including emails, posters, campus events, factsheets/booklets, and mental health first aid training courses.
Number of subjects: 0
Study 24797396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 0
Study 24797396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22814045 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal posterior sub-Tenon cannula
Number of subjects: 159
Study 22814045 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible posterior sub-Tenon cannula
Number of subjects: 159
Study 22814045 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible medium sub-Tenon cannula
Number of subjects: 159
Study 22814045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 159
Study 20400416 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alkane vapocoolant spray
Number of subjects: 62
Study 20400416 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 62
Study 17592908 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group therapy
Number of subjects: 48
Study 17592908 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 48
Study 15273528 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.i.d. (n = 198)
Number of subjects: 397
Study 15273528 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d. (n = 198)
Number of subjects: 397
Study 15273528 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 397
Study 15273528 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 397
Study 11385200 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 12
Study 11385200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar
Number of subjects: 12
Study 11385200 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐2000
Number of subjects: 12
Study 11385200 — intervention group
Group type: COMPARATOR
Intervention: Pertac II
Number of subjects: 12
Study 9342601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg bid)
Number of subjects: 10
Study 9342601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8518523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (6 mg/kg/day)
Number of subjects: 12
Study 8518523 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (2.5 mg/kg/day)
Number of subjects: 12
Study 8518523 — intervention group
Group type: COMPARATOR
Intervention: Control group (children in complete remission and off therapy)
Number of subjects: 12
Study 3688153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookie-decorating activity with altruistic purpose (cookies as a gift for preschool)
Number of subjects: 130
Study 3688153 — intervention group
Group type: COMPARATOR
Intervention: Cookie-decorating activity without altruistic purpose (no gift)
Number of subjects: 130
Study 29759785 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic navigation (RN) ablation
Number of subjects: 258
Study 29759785 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation (MN)
Number of subjects: 258
Study 25986222 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) program
Number of subjects: 44
Study 25986222 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 44
Study 24387685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation then inflation (study group)
Number of subjects: 184
Study 24387685 — intervention group
Group type: COMPARATOR
Intervention: Inflation then fixation (control group)
Number of subjects: 184
Study 21920963 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 172
Study 21920963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 172
Study 20120663 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps Education Device (QED)
Number of subjects: 60
Study 20120663 — intervention group
Group type: COMPARATOR
Intervention: Non-QED
Number of subjects: 60
Study 17943573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ciclesonide 200 microg once daily
Number of subjects: 150
Study 17943573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 17943573 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐BDP 320 microg twice daily during run-in period
Number of subjects: 150
Study 17943573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg on last treatment day
Number of subjects: 150
Study 16358992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory obstetric and gynaecological services
Number of subjects: 635
Study 11599064 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection rate of 0.5 mL/second
Number of subjects: 37
Study 11599064 — intervention group
Group type: COMPARATOR
Intervention: Injection rate of 1.5 mL/second
Number of subjects: 37
Study 11599064 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher injection rates (0.5, 1.5, and 3.0 mL/second) in volunteers
Number of subjects: 37
Study 9725493 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg oral and intravenous doses)
Number of subjects: 11
Study 9725493 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 subjects)
Number of subjects: 11
Study 7528939 — intervention group
Group type: COMPARATOR
Intervention: Best sleeping position
Number of subjects: 20
Study 7528939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal decongestant and position
Number of subjects: 20
Study 7528939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal decongestant alone
Number of subjects: 20
Study 7528939 — intervention group
Group type: COMPARATOR
Intervention: Control night
Number of subjects: 20
Study 7528939 — intervention group
Group type: EXPERIMENTAL
Intervention: Position alone
Number of subjects: 20